Efficacy and Safety of Luspatercept in MDS: Key Data from the COMMANDS Trial

A review of the rationale and study design of the phase 3 COMMANDS trial and subsequent subgroup analysis data recently presented at the ASCO and EHA 2023 Annual Meetings.

EP: 1.Case Presentation: A 72-Year-Old Woman with Single Lineage Dysplasia Myelodysplastic Syndrome (MDS)

EP: 2.Approaches to Diagnosis and Risk Assessment for Patients With MDS

EP: 3.Differences in Treatment Approaches for Low-Risk and High-Risk MDS

EP: 4.Current Unmet Needs for Patients With Low-Risk MDS in the Frontline Setting

EP: 5.Luspatercept as a Treatment Option in MDS

Now Viewing

EP: 6.Efficacy and Safety of Luspatercept in MDS: Key Data from the COMMANDS Trial

EP: 7.Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS

EP: 8.Future Perspectives and Unmet Needs for Patients With MDS

Related Videos